Vomaris Announces Initiation of Study with Walter Reed National Military Medical Center’s Combat Wound Initiative

Chandler, Arizona – February 19, 2013

Vomaris Innovations, Inc., a leading edge regenerative medicine company focusing on wound care with bioelectric technology, is pleased to announce the initiation of a new study with Walter Reed National Military Medical Center.

The objective of the study, funded by the Henry M. Jackson Foundation for the Advancement of Military Medicine, is the assessment of the clinical efficacy of a bioelectric dressing (Procellera®) in conjunction with standard-of-care on the healing rate of chronic soft tissue wounds compared with standard-of-care alone.

In this 50-subject study, the primary endpoint for efficacy will be the rate of healing (healing trajectory) in the treatment group compared to that of the control group, during the 12-week treatment study period. It is hypothesized that a bioelectric dressing will reduce wound healing time when compared to SOC treatment, thereby accelerating wound healing trajectory.

“Walter Reed’s selection of Procellera for a study of this significance is an exceptionally positive indicator for the future of Vomaris, and our proprietary bioelectric technology,” said Michael P. Nagel, Vomaris President and CEO.

“Field experience along with our clinical studies continues to show that Procellera has the potential to transform wound care as we know it today,” Nagel said. “Proving Procellera’s impact in a study associated with the Combat Wound Initiative will provide another layer of critical clinical evidence and establish our cost-savings footprint in the emerging medical device marketplace.”

Procellera is the first totally self-contained, conformable, cut-to-fit, electrically active wound dressing in the world. The technology is extremely versatile and scalable and spans multiple indications.